IX BIOPHARMA LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.04 SGD | -11.11% |
|
-23.08% | -11.11% |
| Mar. 12 | Singaporean Shares End Marginally Higher; Biopharma's Shares Climb 2% on Introduction of New Sublingual Wafer | MT |
| Mar. 12 | IX Biopharma Introduces New Sublingual Wafer | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
IX Biopharma Ltd. is a Singapore-based specialty pharmaceutical and nutraceutical company. The Company is focused on the development, manufacturing and commercialization of innovative therapies for the treatment of acute and breakthrough pain, and other health conditions. It has developed a patented drug delivery platform technology, WaferiX. WaferiX is a novel multi-drug delivery platform comprising a highly porous, amorphous and non-ionic matrix in a solid dosage form. The Company operates through two segments: Specialty Pharmaceutical and Nutraceutical segments. Specialty Pharmaceutical primary business activities are the development, manufacturing and sale of pharmaceutical and medicinal cannabis products. Nutraceutical primary business activities are the sale of nutraceutical products. The Company's pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management.
Sector
Pharmaceuticals
Calendar
2024-08-18
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -11.11% | 25.41M | |
| +24.60% | 672B | |
| +24.08% | 550B | |
| -5.63% | 351B | |
| +15.37% | 317B | |
| +7.38% | 292B | |
| +3.26% | 211B | |
| +0.78% | 203B | |
| -9.69% | 144B | |
| -6.63% | 141B |
- Stock Market
- Equities
- 42C Stock
- News iX Biopharma Ltd.
- IX Biopharma Launches Program to Develop Drug to Treat Agitation in Dementia
